IRL-1620 acetate NEW
| Price | $189 | $469 | $687 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: IRL-1620 acetate | Purity: 96.64% |
| Supply Ability: 10g | Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | IRL-1620 acetate |
| Description | IRL-1620 acetate is an effective and selective agonist of Endothelin B receptor (ETB) with a Ki of 16 pM which is more selective than ETA with a Ki of 19 μM. |
| In vitro | IRL-1620 acetate is 60 times more selective for the ETB receptor than ET-3 (KiETA/ KiETB=1900)[3]. |
| In vivo | IRL-1620 acetate improves both acquisition (learning) and retention (memory) on the water maze task and enhances angiogenic and neurogenic remodeling. Rats treated with IRL-1620 acetate significantly reduces the cognitive impairment induced by Aβ. IRL-1620 acetate treatment enhances the number of blood vessels labeled with VEGF compared to vehicle treatment[1]. IRL-1620 acetate, restores analgesic tolerance to morphine and oxycodone, but it does not affect morphine and oxycodone induced decrease in NGF/PI3K expression. IRL-1620 acetate attenuates opioid tolerance without the involvement of NGF/PI3K pathway[2]. IRL-1620 acetate (1-100 nM) induces contractions of the guinea pig trachea. The effective concentration that produces 30 % of 60 mM KCI-induced contraction is estimated to be 28 nM for IRL 1620[3]. IRL-1620 acetate (1-100 nM) increases cytosolic Ca2+ in the vascular endothelium ([Ca]E) with little effect on resting muscle tone, and relaxes the norepinephrine-stimulated tone with an increase in [Ca]E, in rat aorta[3]. |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Keywords | IRL1620 acetate | IRL 1620 Acetate | IRL1620 Acetate | 142569-99-1 free base | IRL-1620 Acetate | 142569-99-1 | IRL 1620 acetate |
| Inhibitors Related | Bosentan | BMS 182874 hydrochloride | Sulfisoxazole | Ambrisentan | Sparsentan | Aprocitentan |
| Related Compound Libraries | Bioactive Compound Library | Anti-Cancer Clinical Compound Library | Peptide Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $30.00/1mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-11-19 | |
| $50.00/1KG |
VIP1Y
|
hebei hongtan Biotechnology Co., Ltd
|
2024-03-21 | |
| $1.00/1box |
VIP6Y
|
Shanghai Longyu Biotechnology Co., Ltd.
|
2024-11-28 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY